|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US6054312A
(en)
|
1997-08-29 |
2000-04-25 |
Selective Genetics, Inc. |
Receptor-mediated gene delivery using bacteriophage vectors
|
|
ATE363290T1
(de)
|
1999-10-04 |
2007-06-15 |
Novartis Vaccines & Diagnostic |
Cd40 antagonist zur behandlung von psoriasis
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
CA2658221C
(en)
|
2001-04-27 |
2012-11-27 |
Kyowa Kirin Co., Ltd. |
Anti-cd40 monoclonal antibody
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
CN1922316B
(zh)
|
2003-12-25 |
2011-03-23 |
协和发酵麒麟株式会社 |
抗cd40抗体突变体
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
AR060487A1
(es)
|
2006-04-21 |
2008-06-18 |
Xoma Technology Ltd |
Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
|
|
EP2176283B1
(en)
|
2007-07-14 |
2016-11-02 |
University of Iowa Research Foundation |
Methods and compositions for treating brain diseases
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
RS53782B1
(sr)
*
|
2008-10-01 |
2015-06-30 |
Immatics Biotechnologies Gmbh |
Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
|
|
EP2424877A4
(en)
|
2009-04-28 |
2013-01-02 |
Harvard College |
SUPRAGELADENE PROTEINS FOR CELL PENETRATION
|
|
HUE049849T2
(hu)
|
2010-03-31 |
2020-10-28 |
Boehringer Ingelheim Int |
Anti-CD40 antitestek
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US8927514B2
(en)
|
2010-04-30 |
2015-01-06 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
US8628966B2
(en)
|
2010-04-30 |
2014-01-14 |
City Of Hope |
CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
|
|
JP5458188B2
(ja)
|
2011-02-17 |
2014-04-02 |
協和発酵キリン株式会社 |
抗ｃｄ４０抗体の高濃度製剤
|
|
CN105755044A
(zh)
*
|
2011-04-22 |
2016-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
EP2900686B1
(en)
|
2012-09-28 |
2020-06-10 |
The University of North Carolina At Chapel Hill |
Aav vectors targeted to oligodendrocytes
|
|
US20150273016A1
(en)
|
2012-10-17 |
2015-10-01 |
Fondazione Telethon |
Gene therapy for glycogen storage diseases
|
|
KR102270618B1
(ko)
|
2012-10-30 |
2021-06-30 |
아펙시젠, 인코포레이티드 |
항-cd40 항체 및 사용 방법
|
|
EP2928502B1
(en)
|
2012-12-05 |
2019-01-23 |
Ruprecht-Karls-Universität Heidelberg |
Conjugates of proteins and multivalent cell-penetrating peptides and their uses
|
|
EP3492597A3
(en)
*
|
2013-05-21 |
2019-08-28 |
University of Florida Research Foundation, Inc. |
Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
|
|
TN2015000444A1
(en)
|
2013-06-03 |
2017-04-06 |
Novartis Ag |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
|
ES2739288T3
(es)
|
2013-09-13 |
2020-01-30 |
California Inst Of Techn |
Recuperación selectiva
|
|
CN105745326A
(zh)
*
|
2013-10-24 |
2016-07-06 |
优尼科Ip有限公司 |
用于基因治疗神经疾病的aav-5假型载体
|
|
US11053291B2
(en)
|
2014-02-19 |
2021-07-06 |
University Of Florida Research Foundation, Incorporated |
Delivery of Nrf2 as therapy for protection against reactive oxygen species
|
|
AU2015229381B2
(en)
|
2014-03-11 |
2019-11-07 |
University Of Florida Research Foundation, Inc. |
Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
RU2715038C2
(ru)
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Антитела анти-pd-l1 и способы их диагностического применения
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
WO2016138525A1
(en)
|
2015-02-27 |
2016-09-01 |
University Of Washington |
Polypeptide assemblies and methods for the production thereof
|
|
US20180133327A1
(en)
*
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
BR112017022845A2
(pt)
*
|
2015-04-23 |
2018-07-17 |
Nantomics, Llc |
neoepítopos de câncer
|
|
CN104965364B
(zh)
|
2015-07-14 |
2018-03-30 |
武汉华星光电技术有限公司 |
阵列基板及驱动阵列基板的方法
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
CA2947904A1
(en)
|
2015-11-12 |
2017-05-12 |
Pfizer Inc. |
Tissue-specific genome engineering using crispr-cas9
|
|
KR102423442B1
(ko)
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
|
CN106939047B
(zh)
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
|
CA3011939A1
(en)
*
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
US11905312B2
(en)
*
|
2017-02-15 |
2024-02-20 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for gene transfer across the vasculature
|
|
WO2019012176A1
(en)
|
2017-07-11 |
2019-01-17 |
Outotec (Finland) Oy |
WATERING APPARATUS
|
|
EP3808849A1
(en)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3728568A4
(en)
|
2017-12-19 |
2021-10-06 |
The University of North Carolina at Chapel Hill |
METHODS AND COMPOSITIONS FOR DELIVERING VIRAL VECTORS BY THE BLOOD-BRAIN BARRIER
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US20210207167A1
(en)
|
2018-05-16 |
2021-07-08 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
EP3813854A4
(en)
*
|
2018-06-27 |
2022-06-08 |
Precigen, Inc. |
IN VIVO REGULATED POLYTHERAPY FOR THE TREATMENT OF CANCER
|
|
WO2020014471A1
(en)
|
2018-07-11 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for delivery of agents across the blood-brain barrier
|
|
WO2020028751A2
(en)
|
2018-08-03 |
2020-02-06 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
CN113966399A
(zh)
|
2018-09-26 |
2022-01-21 |
加州理工学院 |
用于靶向基因疗法的腺相关病毒组合物
|
|
CN113166208B
(zh)
|
2018-10-02 |
2024-11-22 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US20220143214A1
(en)
|
2019-01-30 |
2022-05-12 |
The Broad Institute, Inc. |
Systems for evolved adeno-associated viruses (aavs) for targeted delivery
|
|
JP2022526018A
(ja)
|
2019-04-11 |
2022-05-20 |
カリフォルニア インスティテュート オブ テクノロジー |
脳内への特異性が増強されたウイルス組成物
|
|
US20230075314A1
(en)
|
2019-04-29 |
2023-03-09 |
Voyager Therapeutics, Inc. |
VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
|
|
WO2021025995A1
(en)
|
2019-08-02 |
2021-02-11 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2022272240A2
(en)
|
2021-06-21 |
2022-12-29 |
The Brigham And Women’S Hospital, Inc. |
Adeno-associated viral (aav) vectors for tissue-targeted expression of therapeutic genes
|